This localized secretion enhances BiTE concentration at the tumor, enabling precise activation of T cells via CD3 binding and simultaneous targeting of tumor-associated antigens (TAAs) like HER2 or EGFR [47,48]. This evidence concerns the gene ERBB2 and neoplasm.